Literature DB >> 11446742

Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation.

K Frauwirth1, N Shastri.   

Abstract

The invariant chain (Ii) is a key player in regulating the MHC Class II antigen presentation pathway. Here we used site-directed mutagenesis to identify functionally important regions of the invariant chain in regulating antigen presentation function in transfected cells. Mutation of Ii residues 42-53 caused a defect in the presentation of the ovalbumin 247-265/A(k) epitope, but not in the inhibition of presentation of two hen egg lysozyme epitopes, HEL34-45/A(k) and HEL74-88/A(b), from endogenously expressed antigens. The mutation did not prevent ER translocation, trimerization, or association with MHC Class II molecules and had no obvious effect on endosomal targeting of Ii. It did, however, increase the half-life of the invariant chain, suggesting that sequences in this region influence the degradation of the invariant chain and as a consequence its function in antigen presentation. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11446742     DOI: 10.1006/cimm.2001.1796

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.

Authors:  Azizul Haque; Laela M Hajiaghamohseni; Ping Li; Katherine Toomy; Janice S Blum
Journal:  Cell Immunol       Date:  2007-12-11       Impact factor: 4.868

Review 2.  Ancient features of the MHC class II presentation pathway, and a model for the possible origin of MHC molecules.

Authors:  Johannes M Dijkstra; Takuya Yamaguchi
Journal:  Immunogenetics       Date:  2018-10-30       Impact factor: 2.846

3.  Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules.

Authors:  Fangfang Chen; Fantao Meng; Ling Pan; Fazhi Xu; Xuelan Liu; Weiyi Yu
Journal:  BMC Immunol       Date:  2012-09-27       Impact factor: 3.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.